Comparison of Body Weight Change Through Different Smeglutide Administration Methods
NCT05616052 on ClinicalTrials.gov · last registry update 2022-11-15
80 participants. Its estimated completion date, 1 December 2023, has passed with no update to the record. Primary outcome, as filed: weight change in kilograms. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.
- Status
- UNKNOWN
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Huashan Hospital
- Sponsor type
- Other
- Enrollment
- 80
- Started
- 2022-12-01
- Primary completion
- 2023-12-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
weight change in kilograms
Conditions studied
Weight Change, Body
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.